Table 1.
Patient baseline and disease characteristics
| Characteristic | N = 30 |
|---|---|
| Median age, years (range) | 61 (30–80) |
| Sex, n (%) | |
| Male | 28 (93.3) |
| Female | 2 (6.7) |
| ECOG performance status, n (%) | |
| 0 | 5 (16.7) |
| 1 | 25 (83.3) |
| Number of prior anticancer therapy regimens, n (%) | |
| 1 | 6 (20.0) |
| 2 | 14 (46.7) |
| ≥ 3 | 10 (33.3) |
| Number of prior lines of therapy for locally advanced or metastatic disease, n (%) | |
| 0 | 5 (16.7) |
| 1 | 14 (46.7) |
| ≥ 2 | 11 (36.7) |
| Type of prior anticancer therapy for locally advanced or metastatic disease, n (%)a | |
| Cytotoxic therapy | 25 (83.3) |
| Monoclonal antibodies therapy | 6 (20.0) |
| Small molecules | 2 (6.7) |
| Tumor cell PD-L1 expression, n (%)b | |
| Positive | 9 (30.0) |
| Negative | 20 (66.7) |
| Not evaluable | 1 (3.3) |
ECOG Eastern Cooperative Oncology Group
aPatients may be included in more than one category
bA threshold of 1% was used to characterize tumors as either PD-L1 positive (≥ 1%) or negative (< 1%) using an anti-PD-L1 antibody clone 73-10